MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$3,369,000
Interest income
$67,000
(109.38%↑ Y/Y)
Change in fair value of
warrant liability
-$11,000
(91.27%↑ Y/Y)
Net loss
-$2,833,000
(-265.08%↓ Y/Y)
Deemed dividend
$433,000
Dividend on preferred
stock
$103,000
Total other income,
net
$15,000
(-98.70%↓ Y/Y)
Interest expense
$63,000
Loss from operations
-$2,848,000
(-47.41%↓ Y/Y)
Selling, general and
administrative
$2,435,000
(192.32%↑ Y/Y)
Research and development
$413,000
(-62.42%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)